GB835638A
(en)
|
1956-12-01 |
1960-05-25 |
Novo Terapeutisk Labor As |
Insulin crystal suspensions having a protracted effect
|
GB840870A
(en)
|
1957-08-03 |
1960-07-13 |
Novo Terapeutisk Labor As |
Improvements in or relating to insulin preparations
|
US3868358A
(en)
|
1971-04-30 |
1975-02-25 |
Lilly Co Eli |
Protamine-insulin product
|
US3758683A
(en)
|
1971-04-30 |
1973-09-11 |
R Jackson |
Insulin product
|
US3984696A
(en)
|
1974-12-11 |
1976-10-05 |
Medi-Ray, Inc. |
Radiation guard for X-ray table
|
US4153689A
(en)
|
1975-06-13 |
1979-05-08 |
Takeda Chemical Industries, Ltd. |
Stable insulin preparation for nasal administration
|
GB1554157A
(en)
|
1975-06-13 |
1979-10-17 |
Takeda Chemical Industries Ltd |
Stable insulin preparation for intra nasal administration
|
GB1527605A
(en)
|
1975-08-20 |
1978-10-04 |
Takeda Chemical Industries Ltd |
Insulin preparation for intranasal administration
|
JPS6033474B2
(ja)
|
1978-05-11 |
1985-08-02 |
藤沢薬品工業株式会社 |
新規なヒアルロニダ−ゼbmp−8231およびその製造法
|
EP0018609B1
(fr)
|
1979-04-30 |
1983-09-21 |
Hoechst Aktiengesellschaft |
Solutions aqueuses de protéines, stables à la dénaturation, procédé pour leur fabrication et leur utilisation
|
US4783441A
(en)
|
1979-04-30 |
1988-11-08 |
Hoechst Aktiengesellschaft |
Aqueous protein solutions stable to denaturation
|
JPS55153712A
(en)
|
1979-05-18 |
1980-11-29 |
Kao Corp |
Insulin pharmaceutical preparation and its production
|
DE3033127A1
(de)
|
1980-09-03 |
1982-04-08 |
Hoechst Ag, 6000 Frankfurt |
Neue analoga des insulins
|
US4367737A
(en)
|
1981-04-06 |
1983-01-11 |
George Kozam |
Multiple barrel syringe
|
EP0083619A1
(fr)
|
1981-07-17 |
1983-07-20 |
Nordisk Insulinlaboratorium |
Preparation therapeutique d'insuline aqueuse stable et son procede de preparation
|
NL193099C
(nl)
|
1981-10-30 |
1998-11-03 |
Novo Industri As |
Gestabiliseerde insuline-oplossing.
|
DE3316363A1
(de)
|
1983-05-05 |
1984-11-08 |
Deutsche Babcock Anlagen Ag, 4200 Oberhausen |
Walzenrost fuer muellverbrennungsanlagen
|
DE3326472A1
(de)
|
1983-07-22 |
1985-02-14 |
Hoechst Ag, 6230 Frankfurt |
Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
|
DE3326473A1
(de)
|
1983-07-22 |
1985-01-31 |
Hoechst Ag, 6230 Frankfurt |
Pharmazeutisches mittel zur behandlung des diabetes mellitus
|
DE3327709A1
(de)
|
1983-07-29 |
1985-02-07 |
Hoechst Ag, 6230 Frankfurt |
Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
|
DE3333640A1
(de)
|
1983-09-17 |
1985-04-25 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
|
DE3345434A1
(de)
|
1983-12-15 |
1985-06-27 |
Siemens AG, 1000 Berlin und 8000 München |
Roentgenuntersuchungstisch
|
CA1244347A
(fr)
|
1984-05-29 |
1988-11-08 |
Eddie H. Massey |
Formule d'insuline stabilisee
|
US4839341A
(en)
|
1984-05-29 |
1989-06-13 |
Eli Lilly And Company |
Stabilized insulin formulations
|
EP0166971B1
(fr)
|
1984-06-09 |
1990-02-28 |
Hoechst Aktiengesellschaft |
Préparations d'insuline, procédé pour leur fabrication et leur application
|
DE3440988A1
(de)
|
1984-11-09 |
1986-07-10 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung
|
US5008241A
(en)
|
1985-03-12 |
1991-04-16 |
Novo Nordisk A/S |
Novel insulin peptides
|
DK347086D0
(da)
|
1986-07-21 |
1986-07-21 |
Novo Industri As |
Novel peptides
|
DK113585D0
(da)
|
1985-03-12 |
1985-03-12 |
Novo Industri As |
Nye peptider
|
IL78425A
(en)
|
1985-04-15 |
1991-05-12 |
Lilly Co Eli |
Intranasal formulation containing insulin
|
US4689042A
(en)
|
1985-05-20 |
1987-08-25 |
Survival Technology, Inc. |
Automatic medicament ingredient mixing and injecting apparatus
|
DE3526995A1
(de)
|
1985-07-27 |
1987-02-05 |
Hoechst Ag |
Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
|
US4837316A
(en)
|
1985-08-29 |
1989-06-06 |
Fujirebio Kabushiki Kaisha |
Alkylamide derivatives with H2 -receptor antagonistic and cytoprotective action
|
PH25772A
(en)
|
1985-08-30 |
1991-10-18 |
Novo Industri As |
Insulin analogues, process for their preparation
|
US4960702A
(en)
|
1985-09-06 |
1990-10-02 |
Codon |
Methods for recovery of tissue plasminogen activator
|
DE3541856A1
(de)
|
1985-11-27 |
1987-06-04 |
Hoechst Ag |
Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
|
US5496924A
(en)
|
1985-11-27 |
1996-03-05 |
Hoechst Aktiengesellschaft |
Fusion protein comprising an interleukin-2 fragment ballast portion
|
DE3636903A1
(de)
|
1985-12-21 |
1987-07-02 |
Hoechst Ag |
Fusionsproteine mit eukaryotischem ballastanteil
|
CA1275922C
(fr)
|
1985-11-28 |
1990-11-06 |
Harunobu Amagase |
Traitement du cancer
|
DE3544295A1
(de)
|
1985-12-14 |
1987-06-19 |
Bayer Ag |
Thermoplastische formmassen mit hoher kriechstromfestigkeit
|
US5614492A
(en)
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
PH23446A
(en)
|
1986-10-20 |
1989-08-07 |
Novo Industri As |
Peptide preparations
|
DE3880346T2
(de)
|
1987-02-25 |
1993-07-29 |
Novonordisk As |
Insulinderivate.
|
US5034415A
(en)
|
1987-08-07 |
1991-07-23 |
Century Laboratories, Inc. |
Treatment of diabetes mellitus
|
DE3726655A1
(de)
|
1987-08-11 |
1989-02-23 |
Hoechst Ag |
Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
|
DK257988D0
(da)
|
1988-05-11 |
1988-05-11 |
Novo Industri As |
Nye peptider
|
US6875589B1
(en)
|
1988-06-23 |
2005-04-05 |
Hoechst Aktiengesellschaft |
Mini-proinsulin, its preparation and use
|
DE3827533A1
(de)
|
1988-08-13 |
1990-02-15 |
Hoechst Ag |
Pharmazeutische zubereitung zur behandlung des diabetes mellitus
|
US4923162A
(en)
|
1988-09-19 |
1990-05-08 |
Fleming Matthew C |
Radiation shield swivel mount
|
DE3837825A1
(de)
|
1988-11-08 |
1990-05-10 |
Hoechst Ag |
Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
|
US5225323A
(en)
|
1988-11-21 |
1993-07-06 |
Baylor College Of Medicine |
Human high-affinity neurotransmitter uptake system
|
HUT56857A
(en)
|
1988-12-23 |
1991-10-28 |
Novo Nordisk As |
Human insulin analogues
|
US4994439A
(en)
|
1989-01-19 |
1991-02-19 |
California Biotechnology Inc. |
Transmembrane formulations for drug administration
|
IL93282A
(en)
|
1989-02-09 |
1995-08-31 |
Lilly Co Eli |
Insulin analogues
|
US5514646A
(en)
|
1989-02-09 |
1996-05-07 |
Chance; Ronald E. |
Insulin analogs modified at position 29 of the B chain
|
DK134189D0
(da)
|
1989-03-20 |
1989-03-20 |
Nordisk Gentofte |
Insulinforbindelser
|
ATE133087T1
(de)
|
1989-05-04 |
1996-02-15 |
Southern Res Inst |
Einkapselungsverfahren
|
US5006718A
(en)
|
1989-07-21 |
1991-04-09 |
Lenhart Mark J |
X-ray shield for X-ray examination table
|
GR1005153B
(el)
|
1989-08-29 |
2006-03-13 |
The General Hospital Corporation |
Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.
|
US5358857A
(en)
|
1989-08-29 |
1994-10-25 |
The General Hospital Corp. |
Method of preparing fusion proteins
|
US5227293A
(en)
|
1989-08-29 |
1993-07-13 |
The General Hospital Corporation |
Fusion proteins, their preparation and use
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
CN1020944C
(zh)
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
US5397771A
(en)
|
1990-05-10 |
1995-03-14 |
Bechgaard International Research And Development A/S |
Pharmaceutical preparation
|
WO1991016929A1
(fr)
|
1990-05-10 |
1991-11-14 |
Novo Nordisk A/S |
PREPARATION PHARMACEUTIQUE CONTENANT DES n-GLYCOFUROLS ET DES n-ETHYLENE GLYCOLS
|
DK155690D0
(da)
|
1990-06-28 |
1990-06-28 |
Novo Nordisk As |
Nye peptider
|
DK10191D0
(da)
|
1991-01-22 |
1991-01-22 |
Novo Nordisk As |
Hidtil ukendte peptider
|
US5272135A
(en)
*
|
1991-03-01 |
1993-12-21 |
Chiron Ophthalmics, Inc. |
Method for the stabilization of methionine-containing polypeptides
|
CA2038597A1
(fr)
|
1991-03-19 |
1992-09-20 |
Jose P. Garzaran |
Methode et preparation pharmaceutique pour le soulagement de la douleur
|
US5614219A
(en)
|
1991-12-05 |
1997-03-25 |
Alfatec-Pharma Gmbh |
Oral administration form for peptide pharmaceutical substances, in particular insulin
|
US6468959B1
(en)
|
1991-12-05 |
2002-10-22 |
Alfatec-Pharm Gmbh |
Peroral dosage form for peptide containing medicaments, in particular insulin
|
CH682806A5
(de)
|
1992-02-21 |
1993-11-30 |
Medimpex Ets |
Injektionsgerät.
|
CH682805A5
(de)
|
1992-02-24 |
1993-11-30 |
Medimpex Ets |
Anzeigeeinrichtung für ein Injektionsgerät.
|
DK36392D0
(da)
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
US5846747A
(en)
|
1992-03-25 |
1998-12-08 |
Novo Nordisk A/S |
Method for detecting glucagon-like peptide-1 antagonists and agonists
|
US5253785A
(en)
|
1992-04-02 |
1993-10-19 |
Habley Medical Technology Corp. |
Variable proportion dispenser
|
DE59305396D1
(de)
|
1992-12-02 |
1997-03-20 |
Hoechst Ag |
Verfahren zur Gewinnung von Proinsulin mit korrekt verbundenen Cystinbrücken
|
JPH08504820A
(ja)
|
1992-12-18 |
1996-05-28 |
イーライ・リリー・アンド・カンパニー |
インシュリン類似体
|
US5358708A
(en)
|
1993-01-29 |
1994-10-25 |
Schering Corporation |
Stabilization of protein formulations
|
US5478323A
(en)
|
1993-04-02 |
1995-12-26 |
Eli Lilly And Company |
Manifold for injection apparatus
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
ATE176482T1
(de)
|
1993-06-21 |
1999-02-15 |
Novo Nordisk As |
Asp-b28-insulinkristalle
|
US5506203C1
(en)
|
1993-06-24 |
2001-02-06 |
Astra Ab |
Systemic administration of a therapeutic preparation
|
US5534488A
(en)
|
1993-08-13 |
1996-07-09 |
Eli Lilly And Company |
Insulin formulation
|
ES2172574T5
(es)
|
1993-11-19 |
2012-11-29 |
Alkermes, Inc. |
Preparación de micropartículas biodegradables que contienen un agente biológicamente activo
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
IT1265271B1
(it)
|
1993-12-14 |
1996-10-31 |
Alcatel Italia |
Sistema di predistorsione in banda base per la linearizzazione adattativa di amplificatori di potenza
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
DE4405179A1
(de)
|
1994-02-18 |
1995-08-24 |
Hoechst Ag |
Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
|
DE4405388A1
(de)
|
1994-02-19 |
1995-08-24 |
Hoechst Ag |
Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
|
EP2036541A1
(fr)
|
1994-03-07 |
2009-03-18 |
Nektar Therapeutics |
Procédés et compositions pour l'administration pulmonaire d'insuline
|
US5474978A
(en)
|
1994-06-16 |
1995-12-12 |
Eli Lilly And Company |
Insulin analog formulations
|
US5559094A
(en)
|
1994-08-02 |
1996-09-24 |
Eli Lilly And Company |
AspB1 insulin analogs
|
ES2151079T3
(es)
|
1994-09-09 |
2000-12-16 |
Takeda Chemical Industries Ltd |
Preparacion de liberacion sostenida que contiene una sal metalica de un peptido.
|
US5879584A
(en)
|
1994-09-10 |
1999-03-09 |
The Procter & Gamble Company |
Process for manufacturing aqueous compositions comprising peracids
|
US5547929A
(en)
|
1994-09-12 |
1996-08-20 |
Eli Lilly And Company |
Insulin analog formulations
|
US5707641A
(en)
|
1994-10-13 |
1998-01-13 |
Pharmaderm Research & Development Ltd. |
Formulations comprising therapeutically-active proteins or polypeptides
|
YU18596A
(sh)
|
1995-03-31 |
1998-07-10 |
Eli Lilly And Company |
Analogne formulacije monomernog insulina
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
CA2223272A1
(fr)
|
1995-05-05 |
1996-11-07 |
Ronald Eugene Chance |
Insuline monocatenaire a bioactivite elevee
|
US5824638A
(en)
|
1995-05-22 |
1998-10-20 |
Shire Laboratories, Inc. |
Oral insulin delivery
|
US6143718A
(en)
|
1995-06-07 |
2000-11-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of Type II diabetes mellutis with amylin agonists
|
AU6011496A
(en)
|
1995-06-08 |
1997-01-09 |
Therexsys Limited |
Improved pharmaceutical compositions for gene therapy
|
DE69632684T2
(de)
|
1995-06-27 |
2005-06-09 |
Takeda Pharmaceutical Co. Ltd. |
Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
|
JPH11292787A
(ja)
|
1995-08-15 |
1999-10-26 |
Asahi Chem Ind Co Ltd |
生理活性ペプチドを含有する経粘膜投与製剤
|
DE19545257A1
(de)
|
1995-11-24 |
1997-06-19 |
Schering Ag |
Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
DE19637230A1
(de)
|
1996-09-13 |
1998-03-19 |
Boehringer Mannheim Gmbh |
Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
|
CA2257119A1
(fr)
|
1996-06-05 |
1997-12-11 |
Boehringer Mannheim Gmbh |
Analogues exendine, procedes permettant de les preparer et medicaments les contenant
|
US5948751A
(en)
|
1996-06-20 |
1999-09-07 |
Novo Nordisk A/S |
X14-mannitol
|
CN1120019C
(zh)
|
1996-06-20 |
2003-09-03 |
诺沃挪第克公司 |
含NaCl的胰岛素制品
|
ES2292189T3
(es)
|
1996-06-20 |
2008-03-01 |
Novo Nordisk A/S |
Preparaciones a base de insulina conteniendo manitol.
|
US6110703A
(en)
|
1996-07-05 |
2000-08-29 |
Novo Nordisk A/S |
Method for the production of polypeptides
|
ES2359031T3
(es)
|
1996-08-08 |
2011-05-17 |
Amylin Pharmaceuticals, Inc. |
Composición farmacéutica que comprende un péptido de exendina-4.
|
US5783556A
(en)
|
1996-08-13 |
1998-07-21 |
Genentech, Inc. |
Formulated insulin-containing composition
|
HU227021B1
(en)
|
1996-08-30 |
2010-05-28 |
Novo Nordisk As |
Glp-1 derivatives
|
US6277819B1
(en)
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6006753A
(en)
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
CA2277112C
(fr)
|
1997-01-07 |
2008-08-26 |
Amylin Pharmaceuticals, Inc. |
Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
WO1998035033A1
(fr)
|
1997-02-05 |
1998-08-13 |
1149336 Ontario Inc. |
Polynucleotides codant la proexendine, et procedes et utilisations correspondants
|
US5846937A
(en)
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
JP3764174B2
(ja)
|
1997-03-20 |
2006-04-05 |
ノボ ノルディスク アクティーゼルスカブ |
肺用組成物において使用するための亜鉛非含有のインスリン結晶
|
US6043214A
(en)
|
1997-03-20 |
2000-03-28 |
Novo Nordisk A/S |
Method for producing powder formulation comprising an insulin
|
US6310038B1
(en)
|
1997-03-20 |
2001-10-30 |
Novo Nordisk A/S |
Pulmonary insulin crystals
|
DE69810481T2
(de)
|
1997-06-13 |
2003-09-25 |
Genentech Inc |
Stabilisierte antikörperformulierung
|
PE79099A1
(es)
|
1997-06-13 |
1999-08-24 |
Lilly Co Eli |
Formulaciones de insulina estables
|
DE19726167B4
(de)
|
1997-06-20 |
2008-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
|
CA2299425A1
(fr)
|
1997-08-08 |
1999-02-18 |
Amylin Pharmaceuticals, Inc. |
Nouveaux composes agonistes de l'exendine
|
DE19735711C2
(de)
|
1997-08-18 |
2001-04-26 |
Aventis Pharma Gmbh |
Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
|
WO1999021573A1
(fr)
|
1997-10-24 |
1999-05-06 |
Eli Lilly And Company |
Analogues d'insuline acylee par un acide gras
|
US6444641B1
(en)
|
1997-10-24 |
2002-09-03 |
Eli Lilly Company |
Fatty acid-acylated insulin analogs
|
ZA989744B
(en)
|
1997-10-31 |
2000-04-26 |
Lilly Co Eli |
Method for administering acylated insulin.
|
ES2230727T3
(es)
|
1997-11-12 |
2005-05-01 |
Alza Corporation |
Procedimiento de administracion dermal de polipeptidos.
|
BR9815670A
(pt)
|
1997-11-14 |
2000-10-17 |
Amylin Pharmaceuticals Inc |
Compostos agonistas de exendina
|
WO1999025728A1
(fr)
|
1997-11-14 |
1999-05-27 |
Amylin Pharmaceuticals, Inc. |
Nouveaux composes agonistes de l'exendine
|
EP1049486A4
(fr)
|
1997-12-05 |
2006-01-04 |
Lilly Co Eli |
Formulations de glp-1
|
US5981964A
(en)
|
1997-12-22 |
1999-11-09 |
Bruce J. McAuley |
Adjustable X-ray shield and on-line dosimetry system using same
|
AU1870099A
(en)
|
1998-01-09 |
1999-07-26 |
Novo Nordisk A/S |
Stabilised insulin compositions
|
JP4677095B2
(ja)
|
1998-02-13 |
2011-04-27 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
エキセンジンおよびglp−1の変力および利尿効果
|
WO1999042482A1
(fr)
|
1998-02-23 |
1999-08-26 |
Neurocrine Biosciences, Inc. |
Methodes de traitement du diabete au moyen d'analogues peptidiques de l'insuline
|
WO1999043708A1
(fr)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Derives de gpl-1 et de l'extendine au profil d'action etendu
|
JP4394279B2
(ja)
|
1998-03-09 |
2010-01-06 |
ジーランド ファーマ アクティーゼルスカブ |
酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
|
ATE269103T1
(de)
|
1998-03-13 |
2004-07-15 |
Novo Nordisk As |
Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
|
CA2334222C
(fr)
|
1998-06-05 |
2010-02-09 |
Technion Research And Development Foundation Ltd. |
Preparation pour nourrissons enrichie en insuline
|
AU6294899A
(en)
|
1998-10-07 |
2000-04-26 |
Medical College Of Georgia Research Institute, Inc. |
Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
US6211144B1
(en)
|
1998-10-16 |
2001-04-03 |
Novo Nordisk A/S |
Stable concentrated insulin preparations for pulmonary delivery
|
ATE277630T1
(de)
|
1998-10-16 |
2004-10-15 |
Novo Nordisk As |
Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung
|
CA2346884A1
(fr)
|
1998-10-16 |
2000-04-27 |
Novo Nordisk A/S |
Preparations d'insuline contenant du menthol et destinees a l'administration par voie pulmonaire
|
US6489292B1
(en)
|
1998-11-18 |
2002-12-03 |
Novo Nordisk A/S |
Stable aqueous insulin preparations without phenol and cresol
|
JP2002529514A
(ja)
|
1998-11-18 |
2002-09-10 |
ノボ ノルディスク アクティーゼルスカブ |
フェノール及びクレゾールを要さない安定なインスリン水性調製物
|
DK1140145T4
(da)
|
1999-01-14 |
2019-07-22 |
Amylin Pharmaceuticals Llc |
Hidtil ukendte exendinagonistformuleringer og fremgangsmåder til indgivelse deraf
|
DE19908041A1
(de)
|
1999-02-24 |
2000-08-31 |
Hoecker Hartwig |
Kovalent verbrückte Insulindimere
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
JP2007204498A
(ja)
|
1999-03-01 |
2007-08-16 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
JP2000247903A
(ja)
|
1999-03-01 |
2000-09-12 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
US6227819B1
(en)
|
1999-03-29 |
2001-05-08 |
Walbro Corporation |
Fuel pumping assembly
|
US6271241B1
(en)
|
1999-04-02 |
2001-08-07 |
Neurogen Corporation |
Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
|
CN1372570A
(zh)
|
1999-04-30 |
2002-10-02 |
安米林药品公司 |
修饰的exendin和exendin激动剂
|
EA003922B1
(ru)
|
1999-05-17 |
2003-10-30 |
Конджачем, Инк. |
Продолжительно действующие инсулинотропные пептиды
|
WO2000074736A1
(fr)
|
1999-06-04 |
2000-12-14 |
Delrx Pharmaceutical Corporation |
Formulations comprenant des particules deshydratees d'agents pharmaceutiques et leur procede de preparation
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
EP1196189A2
(fr)
|
1999-06-25 |
2002-04-17 |
Medtronic MiniMed, Inc. |
Therapie anti diabete a agents multiples
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
DE19930631A1
(de)
|
1999-07-02 |
2001-01-11 |
Clemens Micheler |
Spritzvorrichtung zur Injektion mindestens zweier flüssiger Therapeutika, insbesondere Insuline
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
EP1076066A1
(fr)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides abaissant le taux de glucose sanguin
|
WO2001021154A2
(fr)
|
1999-09-21 |
2001-03-29 |
Rtp Pharma Inc. |
Compositions particulaires, a surface modifiee, de substances biologiquement actives
|
DE19947456A1
(de)
|
1999-10-02 |
2001-04-05 |
Aventis Pharma Gmbh |
C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
|
CA2386228A1
(fr)
|
1999-10-04 |
2001-04-12 |
Chiron Corporation |
Compositions pharmaceutiques liquides stabilisees contenant des polypeptides inhibiteurs de la voie du facteur tissulaire (tfpi)
|
US6720001B2
(en)
|
1999-10-18 |
2004-04-13 |
Lipocine, Inc. |
Emulsion compositions for polyfunctional active ingredients
|
WO2001032157A2
(fr)
|
1999-11-03 |
2001-05-10 |
Bristol-Myers Squibb Company |
Procede utilise pour traiter le diabete
|
EA004631B1
(ru)
|
1999-12-16 |
2004-06-24 |
Эли Лилли Энд Компани |
Полипептидные композиции, обладающие повышенной стабильностью
|
EP1523993A1
(fr)
|
1999-12-16 |
2005-04-20 |
Eli Lilly & Company |
Compositions contenant un polypeptide et ayant une plus grande stabilité
|
US7022674B2
(en)
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
WO2001051071A2
(fr)
|
2000-01-11 |
2001-07-19 |
Novo Nordisk A/S |
Distribution transepitheliale de derives de glp-1
|
US20010012829A1
(en)
|
2000-01-11 |
2001-08-09 |
Keith Anderson |
Transepithelial delivery GLP-1 derivatives
|
AU2001220765A1
(en)
|
2000-01-24 |
2001-07-31 |
Medtronic Minimed, Inc. |
Mixed buffer system for stabilizing polypeptide formulations
|
JP3540240B2
(ja)
|
2000-03-10 |
2004-07-07 |
株式会社栗本鐵工所 |
混合・混練羽根の検査用治具
|
US6395767B2
(en)
*
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
WO2001093837A2
(fr)
|
2000-06-08 |
2001-12-13 |
Eli Lilly And Company |
Poudre proteinique administree par voie pulmonaire
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
US6770620B2
(en)
|
2000-09-18 |
2004-08-03 |
Sanos Bioscience A/S |
Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
|
KR100508695B1
(ko)
|
2001-02-13 |
2005-08-17 |
한국과학기술연구원 |
인슐린의 경구투여용 제형과 그의 제조방법
|
US7060675B2
(en)
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
DE10108211A1
(de)
|
2001-02-20 |
2002-08-22 |
Aventis Pharma Gmbh |
Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
|
DE10108100A1
(de)
|
2001-02-20 |
2002-08-29 |
Aventis Pharma Gmbh |
Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
|
DE10108212A1
(de)
|
2001-02-20 |
2002-08-22 |
Aventis Pharma Gmbh |
Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
|
AU2002248464A1
(en)
*
|
2001-02-21 |
2002-09-12 |
Medtronic Minimed, Inc. |
Stabilized insulin formulations
|
AU2002258428A1
(en)
|
2001-02-26 |
2002-09-12 |
Millennium Pharmaceuticals, Inc. |
Methods for the treatment of metabolic disorders, including obesity and diabetes
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
ES2333942T3
(es)
|
2001-04-02 |
2010-03-03 |
Novo Nordisk A/S |
Precursores de insulina y proceso para su preparacion.
|
CN1160122C
(zh)
|
2001-04-20 |
2004-08-04 |
清华大学 |
一种制备口服胰岛素油相制剂的方法
|
US20030026872A1
(en)
|
2001-05-11 |
2003-02-06 |
The Procter & Gamble Co. |
Compositions having enhanced aqueous solubility and methods of their preparation
|
US7156877B2
(en)
|
2001-06-29 |
2007-01-02 |
The Regents Of The University Of California |
Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
|
FR2827604B1
(fr)
|
2001-07-17 |
2003-09-19 |
Sanofi Synthelabo |
Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
|
JP2005501058A
(ja)
|
2001-07-31 |
2005-01-13 |
ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ |
Glp−1、exendin−4、そのペプチド・アナログ及びその使用
|
US7238663B2
(en)
|
2001-08-28 |
2007-07-03 |
Eli Lilly And Company |
Pre-mixes of GLP-1 and basal insulin
|
WO2003035028A1
(fr)
|
2001-10-19 |
2003-05-01 |
Nektar Therapeutics |
Modulation de la densite de charge pour ameliorer les caracteristiques de proteines sechees par pulverisation
|
WO2003035051A2
(fr)
|
2001-10-19 |
2003-05-01 |
Inhale Therapeutic Systems, Inc. |
Utilisation d'agents sequestrants des protons dans des formulations medicamenteuses
|
PL210437B1
(pl)
|
2001-11-19 |
2012-01-31 |
Novo Nordisk As |
Sposób wytwarzania związków insuliny
|
AU2002366803A1
(en)
|
2001-12-19 |
2003-07-09 |
Millennium Pharmaceuticals, Inc. |
Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
|
AU2002346490A1
(en)
|
2001-12-20 |
2003-07-09 |
Eli Lilly And Company |
Insulin molecule having protracted time action
|
ES2325653T3
(es)
|
2001-12-21 |
2009-09-11 |
Novo Nordisk Health Care Ag |
Composicion liquida de polipeptidos del factor vii.
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
WO2003066084A1
(fr)
|
2002-02-07 |
2003-08-14 |
Novo Nordisk A/S |
Utilisation d'un compose glp-1 dans le traitement de patients gravement atteints
|
US20100069293A1
(en)
|
2002-02-27 |
2010-03-18 |
Pharmain Corporation |
Polymeric carrier compositions for delivery of active agents, methods of making and using the same
|
TWI351278B
(en)
|
2002-03-01 |
2011-11-01 |
Nisshin Pharma Inc |
Agent for preventing and treating of liver disease
|
JP2005526126A
(ja)
|
2002-05-07 |
2005-09-02 |
ノボ ノルディスク アクティーゼルスカブ |
インスリンアスパルト及びインスリンデテミアを含む可溶性製剤
|
ATE496064T1
(de)
|
2002-05-07 |
2011-02-15 |
Novo Nordisk As |
Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
|
EP1513397B1
(fr)
|
2002-05-17 |
2010-04-14 |
Kyowa Hakko Kirin Co., Ltd. |
Ongules transgeniques capables de produire des anticorps humains
|
US7115563B2
(en)
|
2002-05-29 |
2006-10-03 |
Insignion Holding Limited |
Composition and its therapeutic use
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
MXPA04012497A
(es)
|
2002-07-04 |
2005-07-14 |
Zealand Pharma As |
Glp-1 y metodos para tratar la diabetes.
|
DE10235168A1
(de)
|
2002-08-01 |
2004-02-12 |
Aventis Pharma Deutschland Gmbh |
Verfahren zur Reinigung von Preproinsulin
|
CA2499983A1
(fr)
|
2002-09-27 |
2004-04-08 |
Martek Biosciences Corporation |
Regulation glycemique amelioree dans le prediabete et/ou le diabete de type ii au moyen de l'acide docosahexaenoique
|
US7544657B2
(en)
*
|
2002-10-02 |
2009-06-09 |
Zealand Pharma A/S |
Stabilized Exendin-4 compounds
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
EP1583541B1
(fr)
|
2002-11-20 |
2011-01-12 |
NeuroNova AB |
Composes et methodes pour augmenter la neurogenese
|
CN1413582A
(zh)
|
2002-11-29 |
2003-04-30 |
贵州圣济堂制药有限公司 |
盐酸二甲双胍肠溶片及其制备方法
|
AU2003283216A1
(en)
|
2002-12-03 |
2004-06-23 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
GB0309154D0
(en)
|
2003-01-14 |
2003-05-28 |
Aventis Pharma Inc |
Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
|
GB0304822D0
(en)
|
2003-03-03 |
2003-04-09 |
Dca Internat Ltd |
Improvements in and relating to a pen-type injector
|
ATE485051T1
(de)
|
2003-03-04 |
2010-11-15 |
Technology Dev Company Ltd |
Injizierbare insulinzubereitung mit langzeitwirkung und verfahren zur dessen herstellung und verwendung
|
MXPA05009565A
(es)
|
2003-03-11 |
2005-12-02 |
Novo Nordisk As |
Preparaciones farmaceuticas que comprenden insulina estabilizada con acido.
|
US20040186046A1
(en)
|
2003-03-17 |
2004-09-23 |
Pfizer Inc |
Treatment of type 1 diabetes with PDE5 inhibitors
|
BRPI0409600A
(pt)
|
2003-04-29 |
2006-04-18 |
Lilly Co Eli |
análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina
|
CA2527743A1
(fr)
|
2003-06-03 |
2004-12-09 |
Novo Nordisk A/S |
Compositions pharmaceutiques peptidiques stabilisees
|
DE10325567B4
(de)
|
2003-06-05 |
2008-03-13 |
Mavig Gmbh |
Strahlenschutzanordnung mit separierbarer Umhüllung
|
US20050106147A1
(en)
|
2003-08-29 |
2005-05-19 |
Robert Jordan |
Method of promoting graft survival with anti-tissue factor antibodies
|
WO2005021022A2
(fr)
|
2003-09-01 |
2005-03-10 |
Novo Nordisk A/S |
Formulations de peptides stables
|
WO2005023291A2
(fr)
|
2003-09-11 |
2005-03-17 |
Novo Nordisk A/S |
Utilisation d'agonistes de glp-i dans le traitement de patients souffrant de diabete de type i
|
EP1667724A2
(fr)
*
|
2003-09-19 |
2006-06-14 |
Novo Nordisk A/S |
Nouvelles etiquettes d'affinite pour les proteines plasmiques
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
JP4800959B2
(ja)
|
2003-11-13 |
2011-10-26 |
ノヴォ ノルディスク アー/エス |
糖尿病及び過食症を治療するためのglp−1ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物
|
WO2005048950A2
(fr)
|
2003-11-17 |
2005-06-02 |
Biomune, Inc. |
Compositions therapeutiques contre des maladies infectieuses et des tumeurs
|
WO2005061222A1
(fr)
|
2003-12-22 |
2005-07-07 |
Novo Nordisk A/S |
Contenant en plastique transparent, souple et impermeable, destine a stocker des liquides pharmaceutiques
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
WO2005067898A2
(fr)
|
2004-01-07 |
2005-07-28 |
Nektar Therapeutics |
Compositions a liberation prolongee amelioree pour la delivrance de proteines pharmaceutiques
|
US20070027063A1
(en)
|
2004-01-12 |
2007-02-01 |
Mannkind Corporation |
Method of preserving the function of insulin-producing cells
|
US20080090753A1
(en)
|
2004-03-12 |
2008-04-17 |
Biodel, Inc. |
Rapid Acting Injectable Insulin Compositions
|
MXPA06011425A
(es)
|
2004-03-31 |
2007-03-12 |
Johnson & Johnson |
Memiticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos.
|
CA2566873C
(fr)
|
2004-05-20 |
2013-02-12 |
Diamedica Inc. |
Utilisation de combinaisons medicamenteuses pour traiter la resistance a l'insuline
|
EA012281B1
(ru)
|
2004-06-01 |
2009-08-28 |
Арес Трейдинг С.А. |
Способ стабилизации белков
|
US8071624B2
(en)
|
2004-06-24 |
2011-12-06 |
Incyte Corporation |
N-substituted piperidines and their use as pharmaceuticals
|
JP2008504249A
(ja)
|
2004-06-28 |
2008-02-14 |
ノボ ノルディスク アクティーゼルスカブ |
糖尿病を治療するための方法
|
CA2569381A1
(fr)
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Polypeptides biosynthetiques obtenus a partir d'acides amines codes par voie non naturelle
|
ATE400647T1
(de)
|
2004-08-13 |
2008-07-15 |
Hoffmann La Roche |
C-terminale modifikation von polypeptiden
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
US20060073213A1
(en)
|
2004-09-15 |
2006-04-06 |
Hotamisligil Gokhan S |
Reducing ER stress in the treatment of obesity and diabetes
|
WO2006029634A2
(fr)
|
2004-09-17 |
2006-03-23 |
Novo Nordisk A/S |
Compositions pharmaceutiques contenant de l'insuline et un peptide insulinotropique
|
JP2006137678A
(ja)
|
2004-11-10 |
2006-06-01 |
Shionogi & Co Ltd |
インターロイキン−2組成物
|
CA2586771A1
(fr)
|
2004-11-12 |
2006-05-18 |
Novo Nordisk A/S |
Formulations stables de peptides
|
ES2575984T3
(es)
|
2004-11-12 |
2016-07-04 |
Novo Nordisk A/S |
Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
|
DE102004058306A1
(de)
|
2004-12-01 |
2006-07-27 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
|
SE0402976L
(sv)
|
2004-12-03 |
2006-06-04 |
Mederio Ag |
Medicinsk produkt
|
SG158158A1
(en)
|
2004-12-22 |
2010-01-29 |
Centocor Inc |
Glp-1 agonists, compositions, methods and uses
|
US7879361B2
(en)
|
2005-01-04 |
2011-02-01 |
Gp Medical, Inc. |
Nanoparticles for drug delivery
|
US7957939B2
(en)
|
2005-02-01 |
2011-06-07 |
Canberra Industries, Inc. |
Maximum entropy signal detection method
|
US20090142338A1
(en)
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
AU2006235183B2
(en)
|
2005-04-08 |
2011-02-10 |
Amylin Pharmaceuticals, Llc |
Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
|
WO2006125763A1
(fr)
*
|
2005-05-25 |
2006-11-30 |
Novo Nordisk A/S |
Formulations de polypeptides stabilises
|
WO2006131730A1
(fr)
*
|
2005-06-06 |
2006-12-14 |
Camurus Ab |
Formulations d'analogues de glp-1
|
CN102036662B
(zh)
|
2005-06-27 |
2013-02-27 |
新树股份有限公司 |
利用肉豆蔻衣木脂素预防和治疗ppar介导的疾病的方法
|
US20080227847A1
(en)
|
2005-07-07 |
2008-09-18 |
Aditech Pharma Ab |
Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
|
BRPI0615358B8
(pt)
|
2005-08-19 |
2021-05-25 |
Amylin Pharmaceuticals Inc |
usos de composições compreendendo um copolímero biocompatível po-li( lactídeo-co-glicolídeo) e exendina-4.
|
US20090181887A1
(en)
|
2005-09-08 |
2009-07-16 |
Gastrotech Pharma A/S |
Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
|
SI1926749T1
(sl)
|
2005-09-14 |
2011-11-30 |
Sanofi Aventis Deutschland |
Cepitev prekurzorjev insulinov z varianto tripsina
|
JP5072848B2
(ja)
|
2005-09-20 |
2012-11-14 |
ノバルティス アーゲー |
低血糖イベントを低減するためのdpp−iv阻害剤の使用
|
EP1945142B1
(fr)
|
2005-09-26 |
2013-12-25 |
Medtronic, Inc. |
Valve cardiaque prothétique et valvules veineuses
|
DE102005046113A1
(de)
|
2005-09-27 |
2007-03-29 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
|
KR101105871B1
(ko)
|
2005-09-27 |
2012-01-16 |
주식회사 엘지생명과학 |
인 난포자극호르몬의 안정한 용액 제형
|
US8084420B2
(en)
|
2005-09-29 |
2011-12-27 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
WO2007044867A2
(fr)
|
2005-10-11 |
2007-04-19 |
Huntington Medical Research Institutes |
Agents d'imagerie et leurs procédés d'utilisation
|
CA2626398C
(fr)
|
2005-10-24 |
2011-04-19 |
Nestec S.A. |
Preparation de fibres alimentaires et leur methode d'administration
|
CN101309668A
(zh)
|
2005-11-30 |
2008-11-19 |
健乐克斯医药公司 |
经口吸收的药物制剂和用药方法
|
US20100029558A1
(en)
|
2005-12-06 |
2010-02-04 |
Bristow Cynthia L |
Alpha1 proteinase inhibitor peptides methods and use
|
US8293869B2
(en)
|
2005-12-16 |
2012-10-23 |
Nektar Therapeutics |
Polymer conjugates of GLP-1
|
CA2636469A1
(fr)
|
2006-01-05 |
2007-07-19 |
University Of Utah Research Foundation |
Procedes et compositions associees pour l'amelioration de proprietes d'agents pharmacologiques ciblant le systeme nerveux
|
US8343914B2
(en)
|
2006-01-06 |
2013-01-01 |
Case Western Reserve University |
Fibrillation resistant proteins
|
WO2007082381A1
(fr)
|
2006-01-20 |
2007-07-26 |
Diamedica Inc. |
Compositions contenant (s)-béthanéchol et leur utilisation pour traiter la résistance à l'insuline, le diabète de type 2, l'intolérance au glucose et des troubles associés
|
US20070191271A1
(en)
*
|
2006-02-10 |
2007-08-16 |
Dow Pharmaceutical Sciences |
Method for stabilizing polypeptides lacking methionine
|
EP1986674A4
(fr)
|
2006-02-13 |
2009-11-11 |
Nektar Therapeutics |
Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation
|
WO2007098479A2
(fr)
|
2006-02-21 |
2007-08-30 |
University Of Medicine And Dentistry Of New Jersey |
Délivrance localisée d'insuline pour guérison osseuse
|
US20090054305A1
(en)
|
2006-03-15 |
2009-02-26 |
Novo Nordisk A/S |
Mixtures of Amylin and Insulin
|
TW200806317A
(en)
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
EP2004213A1
(fr)
|
2006-04-03 |
2008-12-24 |
Novo Nordisk A/S |
Agonistes du peptide glp-1
|
CN101454019A
(zh)
|
2006-04-12 |
2009-06-10 |
百达尔公司 |
速效和长效胰岛素联合制剂
|
US20100087365A1
(en)
*
|
2006-04-13 |
2010-04-08 |
Roland Cherif-Cheikh |
Pharmaceutical Compositions of Hglp-1, Exendin-4 and Analogs Thereof
|
EP2021368A4
(fr)
|
2006-06-08 |
2010-01-20 |
Diabecore Medical Inc |
Oligomères d'insuline dérivés
|
DE102006031962A1
(de)
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Amidiertes Insulin Glargin
|
US8900555B2
(en)
|
2006-07-27 |
2014-12-02 |
Nektar Therapeutics |
Insulin derivative formulations for pulmonary delivery
|
JP5399244B2
(ja)
|
2006-08-17 |
2014-01-29 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー |
選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド
|
US20090318353A1
(en)
|
2006-08-25 |
2009-12-24 |
Novo Nordisk A/S |
Acylated Exendin-4 Compounds
|
CN101511364B
(zh)
|
2006-09-07 |
2012-08-15 |
奈科明有限责任公司 |
用于糖尿病的治疗组合
|
EP2074141B1
(fr)
|
2006-09-22 |
2016-08-10 |
Novo Nordisk A/S |
Analogues de l'insuline resistants a une protease
|
WO2008124522A2
(fr)
|
2007-04-04 |
2008-10-16 |
Biodel, Inc. |
Formulations contenant de l'amyline
|
WO2008133908A2
(fr)
|
2007-04-23 |
2008-11-06 |
Intarcia Therapeutics, Inc. |
Formulations en suspension de peptides insulinotropes et leurs utilisations
|
WO2008145323A1
(fr)
|
2007-05-31 |
2008-12-04 |
F. Hoffmann-La Roche Ag |
Formulation pharmaceutique comprenant des interférons
|
EP2155303A1
(fr)
|
2007-06-14 |
2010-02-24 |
Sanofi-Aventis Deutschland GmbH |
Ampoule à deux chambres
|
DK2167169T4
(en)
|
2007-06-14 |
2016-05-30 |
Sanofi Aventis Deutschland |
Tokammerkarpule with accessories
|
ES2785056T3
(es)
|
2007-07-02 |
2020-10-05 |
Hoffmann La Roche |
Un dispositivo para la administración de fármacos
|
ATE516013T1
(de)
|
2007-07-06 |
2011-07-15 |
Basf Corp |
Gastroretentive zusammensetzung auf basis eines wasserlöslichen reaktionsprodukts eines vinylgruppen enthaltenden vorläufers
|
EP2581441A1
(fr)
|
2007-08-09 |
2013-04-17 |
Genzyme Corporation |
Procédé de traitement d'une maladie auto-immune avec des cellules souches mésenchymateuses
|
US8575096B2
(en)
|
2007-08-13 |
2013-11-05 |
Novo Nordisk A/S |
Rapid acting insulin analogues
|
CN101366692A
(zh)
*
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
GB0717399D0
(en)
|
2007-09-07 |
2007-10-17 |
Uutech Ltd |
Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
|
GB0717388D0
(en)
|
2007-09-07 |
2007-10-17 |
Uutech Ltd |
Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
|
AU2008303925A1
(en)
|
2007-09-11 |
2009-04-02 |
Mondobiotech Laboratories Ag |
Use of insulin C-peptide, alone or in combination with GLP-1, as a therapeutic agent
|
BRPI0818324B8
(pt)
|
2007-11-01 |
2021-05-25 |
Merck Serono Sa |
formulação líquida contendo hormônio luteinizante (lh) ou uma variante do mesmo, seu uso, sua forma de apresentação, processo para a sua preparação e composição farmacêutica
|
CN101932601B
(zh)
|
2007-11-08 |
2016-08-03 |
诺沃-诺迪斯克有限公司 |
胰岛素衍生物
|
WO2009063072A2
(fr)
|
2007-11-16 |
2009-05-22 |
Novo Nordisk A/S |
Composition pharmaceutique contenant de l'insuline et peptide insulinotropique
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
EP2231191A2
(fr)
|
2007-12-11 |
2010-09-29 |
ConjuChem Biotechnologies Inc. |
Formulation de conjugués de peptides insulinotropes
|
MX2010007342A
(es)
|
2008-01-04 |
2010-08-26 |
Biodel Inc |
Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido.
|
PL2229407T3
(pl)
|
2008-01-09 |
2017-06-30 |
Sanofi-Aventis Deutschland Gmbh |
Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
KR20100111683A
(ko)
|
2008-01-09 |
2010-10-15 |
사노피-아벤티스 도이칠란트 게엠베하 |
극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
|
UA99337C2
(ru)
|
2008-02-08 |
2012-08-10 |
Биодженерикс Аг |
Жидкая лекарственная форма фсг
|
US8343140B2
(en)
*
|
2008-02-13 |
2013-01-01 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
EP2242767A4
(fr)
|
2008-02-19 |
2011-04-06 |
Biocon Ltd |
Procédé d'obtention d'insulines hétérologues purifiées s'exprimant dans des levures
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
WO2009143014A1
(fr)
|
2008-05-23 |
2009-11-26 |
Amylin Pharmaceuticals, Inc. |
Biodosages de l'agoniste du récepteur du glp-1
|
TWI451876B
(zh)
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
EP3412300A1
(fr)
|
2008-06-27 |
2018-12-12 |
Duke University |
Agents thérapeutiques comprenant des peptides de type élastine
|
US8574214B2
(en)
|
2008-08-30 |
2013-11-05 |
Sanofi-Aventis Deutschland Gmbh |
Cartridge and needle system therefor
|
WO2010028055A1
(fr)
|
2008-09-02 |
2010-03-11 |
Biodel, Inc. |
Insuline dotée d’un profil de libération basal
|
CN102209554A
(zh)
|
2008-09-10 |
2011-10-05 |
弗·哈夫曼-拉罗切有限公司 |
用于防止蛋白质氧化降解的组合物和方法
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
CN102281865B
(zh)
*
|
2008-10-15 |
2017-04-05 |
精达制药公司 |
高浓缩药物颗粒、制剂、混悬剂及其应用
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
AU2009305472B2
(en)
|
2008-10-17 |
2013-12-19 |
Sanofi-Aventis Deutschland Gmbh |
Combination of an insulin and a GLP-1 agonist
|
EP2352513B1
(fr)
|
2008-10-30 |
2016-09-14 |
Novo Nordisk A/S |
Traitement du diabète à l'aide d'injections d'insuline avec une fréquence inférieure à une injection par jour
|
JP2009091363A
(ja)
|
2008-11-21 |
2009-04-30 |
Asahi Kasei Pharma Kk |
Pthの安定化水溶液注射剤
|
DK3254616T3
(da)
|
2009-02-04 |
2021-09-06 |
Sanofi Aventis Deutschland |
Medicinsk anordning og fremgangsmåde for tilvejebringelse af oplysninger til glykæmisk kontrol
|
MX2011008416A
(es)
|
2009-02-13 |
2011-09-08 |
Boehringer Ingelheim Int |
Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
|
EP2435061A4
(fr)
|
2009-05-28 |
2013-03-27 |
Amylin Pharmaceuticals Inc |
Composés agonistes du récepteur glp-1 pour amélioration du sommeil
|
US20120241356A1
(en)
|
2009-07-06 |
2012-09-27 |
Sanofi-Aventis Deutschland Gmbh |
Heat- and vibration-stable insulin preparations
|
US20120232002A1
(en)
|
2009-07-06 |
2012-09-13 |
Sanofi-Aventis Deutschland Gmbh |
Slow-acting insulin preparations
|
SI2451437T1
(sl)
|
2009-07-06 |
2017-03-31 |
Sanofi-Aventis Deutschlad Gmbh |
Vodni pripravki, ki vsebujejo metionin
|
US8709400B2
(en)
|
2009-07-27 |
2014-04-29 |
Washington University |
Inducement of organogenetic tolerance for pancreatic xenotransplant
|
JP5732053B2
(ja)
|
2009-07-31 |
2015-06-10 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
持続型インスリン組成物
|
US8642548B2
(en)
|
2009-08-07 |
2014-02-04 |
Mannkind Corporation |
Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
DK2498801T3
(en)
|
2009-11-13 |
2018-05-07 |
Sanofi Aventis Deutschland |
PHARMACEUTICAL COMPOSITION INCLUDING desPro36Exendin-4 (1-39) -Lys6-NH2 AND METHIONIN
|
US20110118178A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
|
EP2554183B1
(fr)
|
2009-11-13 |
2018-04-04 |
Sanofi-Aventis Deutschland GmbH |
Composition pharmaceutique comprenant un agoniste GLP-1, de l'insuline et de la méthionine
|
DK2329848T4
(da)
|
2009-11-13 |
2019-09-09 |
Sanofi Aventis Deutschland |
Lixisenatid som supplerende behandling til insulin glargin og metformin til behandling af type 2-diabetes
|
US20110118180A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
EP2324853B1
(fr)
|
2009-11-13 |
2015-08-26 |
Sanofi-Aventis Deutschland GmbH |
Lixisenatide en tant que traitement d'appoint à la metformine dans le diabète de type 2
|
CN102933200B
(zh)
|
2009-12-18 |
2015-11-25 |
莱迪杜德制药公司 |
包含磷脂的单相凝胶组合物
|
EP2460527A1
(fr)
|
2010-01-21 |
2012-06-06 |
Sanofi |
Composition pharmaceutique pour le traitement d'un syndrome métabolique
|
AU2011217761A1
(en)
|
2010-02-22 |
2012-08-02 |
Case Western Reserve University |
Long-acting insulin analogue preparations in soluble and crystalline forms
|
AR081066A1
(es)
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
Conjugado de insulina donde se usa un fragmento de inmunoglobulina
|
AR080884A1
(es)
|
2010-04-14 |
2012-05-16 |
Sanofi Aventis |
Conjugados de insulina-sirna
|
US8637458B2
(en)
|
2010-05-12 |
2014-01-28 |
Biodel Inc. |
Insulin with a stable basal release profile
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
WO2011144674A2
(fr)
|
2010-05-20 |
2011-11-24 |
Sanofi-Aventis Deutschland Gmbh |
Formulation pharmaceutique comprenant de l'insuline glargine et du sbe4-ss-cyd
|
EP2389945A1
(fr)
|
2010-05-28 |
2011-11-30 |
Sanofi-Aventis Deutschland GmbH |
Composition pharmaceutique comprenant de l'AVE0010 et de l'insuline glargine
|
US9085757B2
(en)
|
2010-06-17 |
2015-07-21 |
Regents Of The University Of Minnesota |
Production of insulin producing cells
|
US8532933B2
(en)
|
2010-06-18 |
2013-09-10 |
Roche Diagnostics Operations, Inc. |
Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
|
WO2012012352A2
(fr)
|
2010-07-19 |
2012-01-26 |
Amidebio, Llc |
Peptides et protéines modifiés
|
KR101823320B1
(ko)
|
2010-08-30 |
2018-01-31 |
사노피-아벤티스 도이칠란트 게엠베하 |
제2형 진성 당뇨병 치료용 약제를 제조하기 위한 ave0010의 용도
|
PL2632478T3
(pl)
|
2010-10-27 |
2020-03-31 |
Novo Nordisk A/S |
Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
|
WO2012065996A1
(fr)
|
2010-11-15 |
2012-05-24 |
Sanofi-Aventis Deutschland Gmbh |
Préparation pharmaceutique contenant de l'insuline glargine et de la maltosyl-ss-cyclodextrine
|
WO2012066086A1
(fr)
|
2010-11-17 |
2012-05-24 |
Sanofi-Aventis Deutschland Gmbh |
Formulation pharmaceutique comprenant de l'insuline glargine et de la sulfobutyléther-7-ss-cyclodextrine
|
US20130331320A1
(en)
|
2010-12-14 |
2013-12-12 |
Novo Nordisk A/S |
Fast-acting insulin in combination with long-acting insulin
|
RU2572703C2
(ru)
|
2011-02-02 |
2016-01-20 |
Санофи-Авентис Дойчланд Гмбх |
Предотвращение гипогликемии у пациентов с сахарным диабетом 2 типа
|
CA2852056C
(fr)
|
2011-03-11 |
2021-08-10 |
Beth Israel Deaconess Medical Center, Inc. |
Anticorps anti-cd40 et leurs utilisations
|
US20120277147A1
(en)
|
2011-03-29 |
2012-11-01 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
US8735349B2
(en)
|
2011-05-13 |
2014-05-27 |
Sanofi-Aventis Deutschland Gmbh |
Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
DK2707017T3
(en)
|
2011-05-13 |
2016-01-04 |
Sanofi Aventis Deutschland |
LIXISENATIDE AND METFORMIN FOR TREATMENT OF DIABETES TYPE 2
|
US20130040878A1
(en)
|
2011-05-13 |
2013-02-14 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in the treatment of diabetes type 2 patients
|
EP2723359A4
(fr)
|
2011-06-24 |
2015-03-11 |
Amylin Pharmaceuticals Llc |
Procédés pour traiter le diabète avec des formulations à libération prolongée d'agonistes de procédé glp-1
|
PT2750699E
(pt)
|
2011-08-29 |
2015-11-03 |
Sanofi Aventis Deutschland |
Acelerómetro pendular
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
HUE028568T2
(en)
|
2011-10-04 |
2016-12-28 |
Sanofi Aventis Deutschland |
For use in the treatment of constriction and / or obstruction of the lysine senate and pancreatic duct system
|
WO2013050378A1
(fr)
|
2011-10-04 |
2013-04-11 |
Sanofi-Aventis Deutschland Gmbh |
Agoniste du glp-1 pour l'utilisation dans le traitement de la sténose et/ou de l'obstruction dans le tractus biliaire
|
CN104066441A
(zh)
|
2011-10-28 |
2014-09-24 |
赛诺菲-安万特德国有限公司 |
2型糖尿病的治疗方案
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
US9522235B2
(en)
|
2012-05-22 |
2016-12-20 |
Kaleo, Inc. |
Devices and methods for delivering medicaments from a multi-chamber container
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
GB201303771D0
(en)
|
2013-03-04 |
2013-04-17 |
Midatech Ltd |
Nanoparticles peptide compositions
|
AU2014283423B2
(en)
|
2013-06-17 |
2019-03-14 |
Sanofi-Aventis Deutschland Gmbh |
Insulin glargine/lixisenatide fixed ratio formulation
|
TW201605489A
(zh)
|
2013-10-25 |
2016-02-16 |
賽諾菲公司 |
賴谷胰島素(insulin glulisine)的穩定調配物
|